Molecular Cancer Therapeutics CTRC-AACR San Antonio Breast Cancer Symposium
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Senatus, P. B.
Right arrow Articles by Fine, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Senatus, P. B.
Right arrow Articles by Fine, R. L.
Mol Cancer Ther. 2006;5:20-28
© 2006 American Association for Cancer Research

Restoration of p53 function for selective Fas-mediated apoptosis in human and rat glioma cells in vitro and in vivo by a p53 COOH-terminal peptide

Patrick B. Senatus1, Yin Li2, Christopher Mandigo1, Gwen Nichols2, Gaetan Moise1, Yuehua Mao2, Melandee D. Brown1, Richard C. Anderson1, Andrew T. Parsa1, Paul W. Brandt-Rauf3, Jeffrey N. Bruce1 and Robert L. Fine2

1 Department of Neurological Surgery; 2 Experimental Therapeutics Program, Division of Medical Oncology, Department of Medicine; and 3 Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University Medical Center, New York, New York

Requests for reprints: Robert L. Fine, Experimental Therapeutics Program, Division of Medical Oncology, Department of Medicine, Columbia University Medical Center, 650 West 168th Street, BB 20-05, New York, NY 10032. Phone: 212-305-1168; Fax: 212-305-7348. E-mail: rlf20{at}columbia.edu

We have shown that a COOH-terminal peptide of p53 (amino acids 361–382, p53p), linked to the truncated homeobox domain of Antennapedia (Ant) as a carrier for transduction, induced rapid apoptosis in human premalignant and malignant cell lines. Here, we report that human and rat glioma lines containing endogenous mutant p53 or wild-type (WT) p53 were induced into apoptosis by exposure to this peptide called p53p-Ant. The peptide was comparatively nontoxic to proliferating nonmalignant human and rat glial cell lines containing WT p53 and proliferating normal human peripheral marrow blood stem cells. Degree of sensitivity to the peptide correlated directly with the level of endogenous p53 expression and mutant p53 conformation. Apoptosis induction by p53p-Ant was quantitated by terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling assay and Annexin V staining in human glioma cells in vitro and in a syngeneic orthotopic 9L glioma rat model using convection-enhanced delivery in vivo. The mechanism of cell death by this peptide was solely through the Fas extrinsic apoptotic pathway. p53p-Ant induced a 3-fold increase in extracellular membrane Fas expression in glioma cells but no significant increase in nonmalignant glial cells. These data suggest that p53 function for inducing Fas-mediated apoptosis in gliomas, which express sufficient quantities of endogenous mutant or WT p53, may be restored or activated, respectively, by a cell-permeable peptide derived from the p53 COOH-terminal regulatory domain (p53p-Ant). p53p-Ant may serve as a prototypic model for the development of new anticancer agents with unique selectivity for glioma cancer cells and it can be successfully delivered in vivo into a brain tumor by a convection-enhanced delivery system, which circumvents the blood-brain barrier. [Mol Cancer Ther 2006;5(1):20–8]


Grant support: NIH grant RO1 CA 82528, Columbia University Cancer Center Translational Award, and Vinzinni Brain Cancer Award (R.L. Fine), NIH grant RO1 CA 89395 (J.N. Bruce), NIH grant RO1 OH 07590 (P.W. Brandt-Rauf), Catherine O'Rourke/American Brain Tumor Association Fellowship (P.B. Senatus), Reza Khatib Fellowship (C. Mandigo), American Brain Tumor Association Medical Student Fellowship (G. Moise), and George Becker Fellowship (M.D. Brown).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: P.B. Senatus and Y. Li contributed equally to the work. J.N. Bruce and R.L. Fine are senior authors.

4 Y. Li and R.L. Fine, unpublished data

5 J.N. Bruce and R.L. Fine, unpublished data.

Received 6/ 7/05; revised 9/19/05; accepted 10/14/05.




This article has been cited by other articles:


Home page
Cancer Res.Home page
E. Guida, A. Bisso, C. Fenollar-Ferrer, M. Napoli, C. Anselmi, J. E. Girardini, P. Carloni, and G. Del Sal
Peptide Aptamers Targeting Mutant p53 Induce Apoptosis in Tumor Cells
Cancer Res., August 15, 2008; 68(16): 6550 - 6558.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.